1. The lactobacillus plantarum HG-23 is characterized in that the preservation number of the lactobacillus plantarum HG-23 is CCTCC No. 2021330.

2. Use of the lactobacillus plantarum HG-23, described in claim 1, in the preparation of a food product or a medicament.

3. The use according to claim 2, wherein the food or medicament is a hypolipidemic food or hypolipidemic medicament; preferably, the food or medicament acts to reduce cholesterol or to reduce triglycerides.

4. The use according to claim 3, wherein the medicament comprises Lactobacillus plantarum HG-23; and a pharmaceutically acceptable non-toxic carrier.

5. The use of claim 4, wherein the medicament is in a dosage form selected from at least one of tablets, granules, powders, capsules, suspensions, emulsions, lyophilized formulations; preferably, the medicament is a compound probiotic tablet.

6. Use according to claim 3, wherein the food product comprises Lactobacillus plantarum HG-23, according to claim 1, together with a dietetically acceptable additive; preferably, the food product is a probiotic solid powder.

Background

Hypercholesterolemia, also known as hyper-and hypo-lipoprotein cholesterolemia, is the leading risk factor for atherosclerotic cardiovascular disease. Recent studies have shown that for every 1mmol/L reduction in low density lipoprotein in populations at risk for various cardiovascular diseases, the major vascular events can be reduced by 21%. According to the statistics of 2013, about 2 hundred million critical hypercholesterolemia people and 8800 ten thousand hypercholesterolemia patients exist in China.

The methods of drug therapy and dietary intervention are mainly used at present to control and reduce blood lipid levels. Statins and fibrates are used in clinic, the curative effect of the drugs in the initial stage is obvious, but side effects with different degrees are generated along with long-term use, so that the health problems of patients are aggravated, for example, myopathy, rhabdomyolysis, abnormal blood sugar, hepatitis, renal dysfunction and the like are easily induced by long-term use of statins, and the liver injury is serious and the risk of gallstones is increased by long-term use of fibrates. The diet of low-fat or low-saturated fat food can effectively reduce the content of cholesterol in serum, but the taste and flavor of the low-fat food are simpler, the diet proposal is not accepted by the public or persisted for a long time, and the diet is easy to rebound after being careless, so that the eating of the functional food for reducing blood fat is a more ideal method for controlling blood fat for a long time.

At present, the research on the blood fat reduction of probiotics lasts for nearly half a century, and two bacterial strains which are deeply researched for the blood fat reduction function in China belong to lactobacillus plantarum, namely L.plantarum P8 and lactobacillus plantarum ST-III. L.plantarum P8 comes from the team of Zhang Ping leading of the university of inner Mongolia agriculture, and animal experiments show that L.plantarum P8 has a remarkable blood lipid reducing effect. The lactobacillus plantarum ST-III researched and developed by a team leading to the university of Kuo and the university of Jiangnan, the general manager of the Ministry of food college of agriculture of northeast China and the Ministry of the Guangming milk industry successfully proves the effect of reducing cholesterol through animal experiments and population clinical experiments, is industrialized, and becomes a probiotic product with independent intellectual property rights of the Ministry of Guangming.

Therefore, the safe and effective lactobacillus with the function of regulating blood fat is developed, and has wide application prospect in the fields of fermented food and medicine.

In view of this, this patent is filed.

Disclosure of Invention

In order to solve the problems in the prior art, the invention provides a lactobacillus plantarum HG-23 strain and application thereof, wherein the strain can resist gastric acid and bile salt, survive and colonize in intestinal tracts, mediate and improve the intestinal microecological balance of hosts, regulate blood fat and specifically reduce cholesterol and triglyceride.

The invention aims to provide lactobacillus plantarum HG-23.

Another object of the present invention is to provide the use of Lactobacillus plantarum HG-23 described above.

According to the lactobacillus plantarum HG-23 of the embodiment of the invention, the preservation number of the lactobacillus plantarum HG-23 is CCTCC No. 2021330.

The use of Lactobacillus plantarum HG-23 according to a particular embodiment of the invention in the preparation of a food product or medicament for lowering blood lipid.

Preferably, the food or medicament is a cholesterol and triglyceride lowering food or medicament.

The use of lactobacillus plantarum HG-23 according to an embodiment of the invention for the preparation of a medicament, further comprising said lactobacillus plantarum HG-23; and a pharmaceutically acceptable non-toxic carrier.

The use of lactobacillus plantarum HG-23 according to an embodiment of the present invention for the preparation of a medicament, further, in a dosage form selected from at least one of a tablet, a granule, a powder, a capsule, a suspension, an emulsion, and a lyophilized preparation; preferably, the medicament is a compound probiotic tablet.

The medicine also comprises pharmaceutically acceptable auxiliary materials. The pharmaceutically acceptable excipients include, but are not limited to: pharmaceutically acceptable carriers, diluents, fillers, binders and other excipients. Such carriers include, but are not limited to, starch or derivatives thereof, lactose, polyethylene glycol; such diluents include, but are not limited to, starch or derivatives thereof, lactose, sucrose, vegetable oils, waxes, fatty acids; fillers include, but are not limited to talc; the adjuvants may also include, for example, preservatives, lubricants, dispersants, flavoring agents, humectants, antioxidants, colorants, stabilizers, buffers, pH adjusters. Such materials may be desirable to aid in the stability of the formulation or to aid in the enhancement of activity or bioavailability or to produce an acceptable mouthfeel or odor upon oral administration.

Use of Lactobacillus plantarum HG-23 according to an embodiment of the invention for the preparation of a food product, further comprising said Lactobacillus plantarum HG-23, together with a dietetically acceptable additive.

The term "food" as used in the present invention is meant to be understood in a broad sense and may be in any form that can be used, i.e. the food of the present invention may be a health product, a drink, a fermented food, etc. in addition to the conventional forms of food.

Preferably, the food product is a probiotic solid powder. The formulation of a probiotic solid powder will be elucidated in detail in the examples.

According to the application of the lactobacillus plantarum HG-23 in preparing food, in particular to the application of the lactobacillus plantarum HG-23 in preparing food, the probiotic solid powder is prepared from xylooligosaccharide, inulin, fructooligosaccharide, lemon fruit powder and lactobacillus plantarum HG-23.

According to the application of the lactobacillus plantarum HG-23 in preparing food or medicines, the lactobacillus plantarum HG-23 is further freeze-dried powder; the freeze-dried powder is prepared by freeze-drying a bacterial suspension of lactobacillus plantarum HG-23 in a freeze dryer under a sterile environment.

Compared with the prior art, the invention has the following beneficial effects:

(1) the lactobacillus plantarum HG-23 obtained by screening can tolerate gastric acid and bile salt, survive and colonize in intestinal tracts, mediate and improve the intestinal tract microecological balance of hosts, play beneficial effects and generate exact health efficacy; in particular, it is shown to reduce triglyceride and cholesterol in blood.

(2) The lactobacillus plantarum HG-23 obtained by screening can be used for preparing food and medicines for reducing cholesterol and triglyceride, and tests show that the obtained food also has the effect of reducing cholesterol and triglyceride.

Drawings

In order to more clearly illustrate the embodiments or technical solutions of the present invention, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.

FIG. 1 shows the degradation rate of Lactobacillus plantarum HG-23 for cholesterol according to example 2 of the present invention, with the abscissa being the group (blank control, commercial strain, HG-23) and the ordinate being the degradation rate of cholesterol in vitro;

FIG. 2 is a graph showing gastric acid resistance of Lactobacillus plantarum HG-23, in accordance with example 4 of the present invention, on the abscissa, time and on the ordinate, the number of viable bacteria of the HG-23 strain in simulated gastric fluid at pH 2;

FIG. 3 is a graph showing the bile salt resistance of Lactobacillus plantarum HG-23, in accordance with example 4, with time on the abscissa and OD of HG-23 strain in MRS medium and MRS medium containing 0.3% bile salt on the ordinate;

FIG. 4 is a graph showing the ability of Lactobacillus plantarum HG-23 to reduce TG content in vivo, with the abscissa representing the group and the ordinate representing the concentration of triglyceride, according to example 5 of the present invention;

FIG. 5 is a graph showing the ability of Lactobacillus plantarum HG-23 to reduce TC content in vivo, with the abscissa representing the group and the ordinate representing the concentration of cholesterol, according to an embodiment of the present invention;

FIG. 6 is a graph showing the results of an animal experiment in which probiotic solid powder was used to degrade Triglyceride (TG), according to example 6 of the present invention, the abscissa represents the group and the ordinate represents the concentration of triglyceride;

fig. 7 is a graph showing the results of an animal experiment in which probiotic solid powder degrades cholesterol (TC) according to specific example 6 of the present invention, the abscissa represents the group, and the ordinate represents the concentration of cholesterol.

Detailed Description

In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without any inventive step, are within the scope of the present invention.

The lactobacillus plantarum HG-23 is lactic acid bacteria, can effectively reduce cholesterol and triglyceride, can be used as a component of food and medicines, and can improve the symptoms of hyperlipidemia of human bodies.

The new strain Lactobacillus plantarum HG-23 (classification name: Lactobacillus plantarum; Latin name: Lactobacillus plantarum) of the invention has been deposited in the China center for type culture Collection at 6/4 in 2021, with the addresses of the deposition units: china center for type culture Collection in Wuchang Lodojia mountain Wuhan university, with the preservation number of CCTCC No. 2021330; viability was tested by the depository at 2021, 4-6 months with the results: and (6) survival.

In some more specific embodiments, the Lactobacillus plantarum HG-23 is used for the preparation of a food product or a medicament for lowering cholesterol.

Further, the medicament comprises the lactobacillus plantarum HG-23; and a pharmaceutically acceptable non-toxic carrier.

Preferably, the medicament is a compound probiotic tablet.

The food comprises the lactobacillus plantarum HG-23 and a dietetic acceptable additive.

Preferably, the food product is a probiotic solid powder.

Furthermore, the probiotic solid powder is prepared from xylo-oligosaccharide, inulin, fructo-oligosaccharide, lemon fruit powder and lactobacillus plantarum HG-23; the lactobacillus plantarum HG-23 is freeze-dried powder; the freeze-dried powder is prepared by freeze-drying a bacterial suspension of lactobacillus plantarum HG-23 in a freeze dryer under a sterile environment.

The technical solution of the present invention will be described in further detail below by way of examples with reference to the accompanying drawings. However, the examples are chosen only for the purpose of illustrating the invention and are not to be construed as limiting the scope of the invention.

Example 1 isolation and identification of Lactobacillus plantarum HG-23

1. Culture medium formula optimization

And (3) performing an optimized culture medium experiment in groups to finally obtain the optimal formula of the lactic acid bacteria culture medium:

MRS solid culture medium 1L formula: casein peptone 10.0g/L, beef extract 10.0g/L, yeast extract 5.0g/L, glucose 20.0g/L, dipotassium hydrogen phosphate 2.0g/L, tween 801.0g/L, triammonium citrate 2.0g/L, sodium acetate 5.0g/L, magnesium sulfate 0.1g/L, manganese sulfate 0.05g/L, agar 17.5 g; sterilizing at 121 deg.C for 20min at pH 6.5.

MRS broth culture medium formula: casein peptone 10.0g/L, beef extract 10.0g/L, yeast extract 5.0g/L, glucose 20.0g/L, dipotassium hydrogen phosphate 2.0g/L, tween 801.0g/L, triammonium citrate 2.0g/L, sodium acetate 5.0g/L, magnesium sulfate 0.1g/L, manganese sulfate 0.05g/L, pH6.5, and sterilizing at 121 ℃ for 20 min.

2. Strain screening

The Lactobacillus plantarum HG-23 strain is derived from intestinal tracts of healthy people and is separated from feces of healthy adults. Taking the feces of healthy adults, diluting the sample by 10 times of gradient with sterile normal saline to 10-³And coating the lactobacillus strain on an MRS solid culture medium, culturing for 24-48h in an incubator at 37 ℃, observing the morphological characteristics of bacterial colonies, picking suspected bacterial colonies of lactobacillus on the MRS solid culture medium, respectively transferring the suspected bacterial colonies to an MRS liquid culture medium for pure culture, totally separating 5 strains, and numbering each strain.

The acid and cholate tolerance and the cholesterol-reducing ability of the strains obtained by separation and purification are measured, the detailed experimental steps are shown in example 2 and example 3, and lactobacillus plantarum HG-23 with strong acid and cholate tolerance and strong cholesterol-reducing ability is obtained by screening.

3. Strain identification

Extracting bacterial total DNA from the screened lactobacillus plantarum HG-23, and carrying out 16s rDNA amplification, wherein the primers are as follows:

sgF:5'-AGAGTTTGATCATGGCTCAG-3'(SEQ ID NO：1)

sgR:5'-TAGGGTTACCTTGTTACGACTT-3'(SEQ ID NO：2)

the primers are used for PCR amplification and agarose gel electrophoresis, and then gel cutting, recovery and sequencing are carried out.

The sequencing result of the 16s DNA of the strain obtained by separation is shown as SEQ ID NO. 3.

Example 2 in vitro cholesterol removal assay of Lactobacillus plantarum HG-23

The in vitro cholesterol removal rate of the strain is detected according to the following steps, and a commercial strain lactobacillus plantarum 299V is taken as an experimental control group, and the method specifically comprises the following steps:

transferring the test strain into MRS liquid culture medium, culturing at 37 deg.C for 24h, subculturing for 2 times with 1% inoculum size, and culturing at 37 deg.C for 15 h. Preparing a liquid MRS culture medium, and sterilizing for later use;

preparing an MRS medium (culture solution MRSO-CHOL) containing cholesterol: the medium consists of MRS liquid medium, sodium thioglycollate, bile salt and cholesterol, wherein the concentration of the sodium thioglycollate in the culture solution MRSO-CHOL is 2g/L, the concentration of the bile salt in the culture solution MRSO-CHOL is 0.3%, and the concentration of the cholesterol is 120 ug/ml.

Experimental groups: the activated lactobacillus plantarum HG-23 bacterial liquid is inoculated into 10ml of culture solution MRSO-CHOL according to the inoculation amount of 1%.

Positive control group: the bacterial solution of the activated commercial strain was inoculated in 10ml of the culture solution MRSO-CHOL at an inoculum size of 1%.

Blank control group: 10ml of the culture broth MRSO-CHOL without the inoculated strain.

Placing the two groups of samples in a constant-temperature incubator at 37 ℃ for 24h, taking out and shaking up, centrifuging for 15min at 4000r/m, taking supernatant, measuring the content of cholesterol in the supernatant by using an o-phthalaldehyde color developing agent, and calculating the removal rate of the cholesterol.

Wherein, the cholesterol removal rate is the difference between the cholesterol of the control group and the cholesterol of the experimental group/the cholesterol content of the control group.

The experimental result is shown in figure 1, the cholesterol reduction rate of the lactobacillus plantarum HG-23 is 70.94%, which indicates that the lactobacillus plantarum HG-23 has stronger in-vitro cholesterol reduction capability.

Example 3 bacterial safety test of Lactobacillus plantarum HG-23

(1) Antibiotic susceptibility testing

HG-23 antibiotic resistance was tested by microdilution. Test antibacterial drugs (Gentamicin, Kanamycin, Tetracycline, Erythromycin, Clindamycin, Chloramphenicol, Amplicilin, the initial concentrations of which are 1024ug/ml, 256ug/ml, 64ug/ml, 8ug/ml, 16ug/ml, 64ug/ml and 16ug/ml) are diluted for 12 times in a series of ratios, the diluted test bacterial liquid in 2ml is added into corresponding holes of a 96-well plate respectively, the test bacterial liquid is cultured for 48 hours and observed, and the test bacterial liquid is the Minimum Inhibitory Concentration (MIC) hole of the antibacterial drugs, namely the sensitivity of the test strain. The results of the experiment are shown in table 1:

TABLE 1 results of resistance test of Lactobacillus plantarum HG-23 to antibiotics

Antibiotic (mg/mL)	HG-23	EFSA specifies safety values (Lactobacillus plantarum)
			Gentamicin	8	16
Kanamycin	32	64
			Tetracycline	16	32
Erythromycin	0.5	1
			Clindamycin	0.5	2
Chloramphenicol	2	8
			Amplicilin	1	2

As can be seen from Table 1, the results of the antibiotic resistance test of Lactobacillus plantarum HG-23 indicate that the MIC of the antibiotic is within a safe range.

(2) Metabolite toxicity detection

And (3) detecting the optical activity of the lactic acid: the detection was carried out using D-/L-lactic acid detection kit from Megazyme of Ireland. The experimental result shows that D-lactic acid is not produced.

Nitrate reductase activity assay: under aseptic conditions, inoculating the activated strain into a nitrate culture medium according to the inoculation amount of 3 percent, culturing for 5 days at 37 ℃, dropwise adding 10 drops of potassium iodide solution and 10 drops of starch solution respectively, and observing the experimental result. And simultaneously, carrying out a blank experiment. The experimental results show that all bacteria liquid are not changed into blue, and the bacteria liquid is negative reaction.

Indole experiments: under the aseptic condition, the activated strain is inoculated into peptone water nutrient medium according to 3 percent of inoculation amount. Culturing at 37 ℃ for 72h, adding 8-10 drops of indole reagent, and observing the experimental result. And simultaneously, carrying out a blank experiment. The experimental result shows that red rings do not appear, and the metabolism does not produce indole.

Detecting the activity of amino decarboxylase: bacteria having an amino acid decarboxylase decompose an amino acid to decarboxylate the amino acid to produce an amine (lysine → cadaverine, ornithine → putrescine, arginine → spermine) and carbon dioxide, make the medium alkaline, and drop-add an indicator (bromocresol purple), which is yellow negative and purple positive. The experimental results showed that the assay tube was yellow and negative.

(3) Determination of cell adhesion Capacity

Culturing the cell monolayer culture in the 6-well plate for 1h at the constant temperature of 37 ℃ by using incomplete DMEM (without serum and double antibody); sucking out the culture solution, washing with sterile PBS for 3 times, and sucking the washing solution to dry; 500. mu.L of 10 was taken⁸Uniformly mixing cfu/mL experimental strains with 500 mu L incomplete DMEM, adding the mixture into a 6-hole culture plate, setting a blank control of only bacteria liquid without cells, and culturing at 37 ℃ for 1.5h at constant temperature; taking out the culture plate, sucking the culture solution to dry, washing with sterile PBS for 5 times, and sucking the washing solution to dry; adding 10% of formaldehyde into each hole, and fixing for 2 hours at room temperature; sucking dry the stationary liquid, washing for 3 times by sterile PBS, sucking dry the washing liquid, and drying at room temperature; microscopic examination after gram staining, randomly selecting 20 fields for counting, and calculating the adhesion index:

adhesion index-number of bacteria per cell (i.e.average number of bacteria adhered per cell)

The bacterial strain randomly selects 20 fields, counts the total number of bacteria adhered to cells in the fields and the number of the cells, and determines the adhesion index, and the experimental result shows that HG-23 has 5.6 of the adhesion index of HT-29 of a human colon cancer cell line and has better cell adhesion capacity.

EXAMPLE 4 in vitro acid and bile salt tolerance test of Lactobacillus plantarum HG-23

Preparing simulated gastric fluid SGF (2.0g NaCl, 3.2g pepsin (pepsin) and a proper amount of concentrated hydrochloric acid to adjust the pH value to 3.0), and filtering the mixture by using a 0.2 mu m microporous membrane for later use. Selecting slant strains to be cultured in an MRS liquid culture medium for 16-18 h at 37 ℃. Centrifuging the bacterial suspension at 4000r/min for 15min, removing supernatant, weighing wet weight of the bacterial strain, suspending the bacterial strain in physiological saline according to the weight ratio of 0.1g/ml, and adding the bacterial strain into the saline according to the weight ratio of 1: adding the mixture of 10 into SGF solution, mixing uniformly, culturing in a constant temperature incubator at 37 ℃ for 2h, and counting cells. The experimental result is shown in figure 2, the number of the viable bacteria is kept at an order of magnitude, and the lactobacillus plantarum HG-23 has strong acid resistance in vitro.

The twice activated bacterial liquid is inoculated into 10mL MRS liquid culture medium containing 0.3% cholate according to the amount of 1% for culture and growth curve determination, and the experimental result is shown in figure 3, which shows that HG-23 has stronger bile resistance in vitro.

Example 5 in vivo efficacy Studies (animal experiments) of Lactobacillus plantarum HG-23

(1) Preparation of the experimental strains:

inoculating the twice activated lactobacillus plantarum HG-23 into MRS liquid culture medium, culturing at 37 ℃ for 18h, centrifuging at 6000r/m for 10min, washing with sterilized normal saline, and collecting the thallus. Then, 0.85% physiological saline was added to adjust the number of bacteria to about 1.0X 10⁹CFU/ml, then subpackaging viable bacteria into 15ml centrifuge tubes according to daily dosage, taking dosage of 2 ml/each daily, 10 each group, and 4 groups, and requiring intragastric administration for 28 days.

(2) Grouping and feeding modes of experimental animals:

Sprague-Dawley line 5 week old male rats, 40 in total, were freely fed to day 28, and were divided on average into 4 groups of 10 animals per group:

HG-23 group: feeding live bacteria suspension for intragastric administration with high-fat feed;

model group: intragastric feeding 0.85% normal saline, and feeding high fat feed;

normal group: gavage 0.85% normal saline, and feeding standard feed;

blood fat recovery group: gavage a standard dose of Xuezhikang, and feeding high-fat feed.

Each 2ml of the mixture is infused in the stomach for 28 days every day, and then the infusion is stopped, and the feed and water of each group are unchanged for 28 days.

(3) Sample collection and analytical testing:

blood was collected before the official test, on day 28 and at time intervals. The blood collection method comprises collecting blood in femoral vein of rat after eating overnight, centrifuging at 4000r/m for 10min after blood coagulation, separating serum by using kit (name: total cholesterol determination kit, company: Ou diagnosis products Co., Ltd., Jiang Dong, Zhe) and color-changing acid color development method, enzyme labeling instrument (company: molecular Devices, model: spectra MAX190) were tested for cholesterol and triglycerides, respectively.

(4) Results of the experiment

The results of the experiment are shown in FIGS. 4 and 5. After 28 days of feeding hyperlipidemic rats with the bacterial suspension containing the strain HG-23, femoral vein blood drawing tests show that Triglyceride (TG) and cholesterol (TC) in the rat blood are respectively reduced by 25% and 27.6% compared with a control, which indicates that the lactobacillus plantarum HG-23 has the effect of reducing cholesterol and triglyceride in the rat body.

Example 6

A method for preparing composite probiotic solid powder for regulating blood lipid is provided. The paint comprises the following components in percentage by weight: 30% of lemon fruit powder, 22% of fructo-oligosaccharide, 20% of xylo-oligosaccharide, 20% of inulin and 8% of lactobacillus plantarum HG-23 bacterial powder.

Animal experiments prove that the lactobacillus plantarum HG-23 effectively reduces the levels of cholesterol and triglyceride in serum. The fructo-oligosaccharide, xylo-oligosaccharide and inulin are prebiotics and can promote the proliferation of probiotics. In addition, various studies at home and abroad show that fructo-oligosaccharide, xylo-oligosaccharide and inulin can reduce the concentration of triglyceride and cholesterol in serum, thereby improving lipid metabolism. The formula also has the advantages of natural components, scientific formula, balanced nutrition, convenient taking, good solubility and no sticking to teeth.

The composite probiotic solid powder is prepared by the following process steps:

(1) freeze-drying powder preparation: freeze-drying the bacterial suspension of Lactobacillus plantarum HG-23 in sterile environment by freeze dryer to obtain Lactobacillus plantarum HG-23 lyophilized powder with vacuum degree of 6Pa, freezing temperature of-40 deg.C, and freeze-drying time ofWherein the viable count of each gram of lactobacillus plantarum HG-23 freeze-dried powder is 5 multiplied by 10¹¹cfu, waterThe content of the components is less than 5 percent;

(2) preparing materials: transferring the lactobacillus plantarum HG-23, the lemon fruit powder, the fructo-oligosaccharide, the xylo-oligosaccharide, the inulin and the raw materials into a 10 ten thousand grade clean area, sampling and inspecting;

(3) sieving: after the inspection is qualified, respectively sieving the raw materials by a 80-mesh sieve, and weighing the raw materials according to the proportion;

(4) mixing: mixing the weighed raw materials while stirring, and mixing to obtain a mixed powder with consistent color and no color difference;

(5) packaging: and packaging the mixed powder according to the measured weight, labeling and boxing to obtain a finished product.

The composite probiotic solid powder for regulating blood fat obtained in example 6 was subjected to a drug effect test.

Test protocol: experimental protocol As in example 5, the intragastric sample was changed to a suspension prepared by adding sterile water to the probiotic solid powder, and the number of bacteria was adjusted to about 1X 10⁹CFU/mL, the dose is 2 mL/mouse per day.

After the high-fat rats are fed with the suspension of the probiotic solid powder for 28 days, femoral vein blood drawing detection shows that the results are shown in fig. 6 and 7, and the fact that triglyceride and cholesterol in the blood of the rats are obviously reduced compared with the control is found, lactobacillus plantarum HG-23 is fixedly planted in the rats and plays a role, and the probiotic solid powder is proved to have the effect of reducing triglyceride and cholesterol in the rats after intragastrically administration.

The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.

SEQUENCE LISTING

<110> Shenzhen Shenhua Dai agricultural application research institute

<120> Lactobacillus plantarum HG-23 strain and application thereof

<130> 202104

<160> 3

<170> PatentIn version 3.3

<210> 1

<211> 20

<212> DNA

<213> unknown

<400> 1

agagtttgat catggctcag 20

<210> 2

<211> 22

<212> DNA

<213> unknown

<400> 2

tagggttacc ttgttacgac tt 22

<210> 3

<211> 1371

<212> DNA

<213> unknown

<400> 3

tgcttgcatc atgatttaca tttgagtgag tggcgaactg gtgagtaaca cgtgggaaac 60

ctgcccagaa gcgggggata acacctggaa acagatgcta ataccgcata acaacttgga 120

ccgcatggtc cgagcttgaa agatggcttc ggctatcact tttggatggt cccgcggcgt 180

attagctaga tggtggggta acggctcacc atggcaatga tacgtagccg acctgagagg 240

gtaatcggcc acattgggac tgagacacgg cccaaactcc tacgggaggc agcagtaggg 300

aatcttccac aatggacgaa agtctgatgg agcaacgccg cgtgagtgaa gaagggtttc 360

ggctcgtaaa actctgttgt taaagaagaa catatctgag agtaactgtt caggtattga 420

cggtatttaa ccagaaagcc acggctaact acgtgccagc agccgcggta atacgtaggt 480

ggcaagcgtt gtccggattt attgggcgta aagcgagcgc aggcggtttt ttaagtctga 540

tgtgaaagcc ttcggctcaa ccgaagaagt gcatcggaaa ctgggaaact tgagtgcaga 600

agaggacagt ggaactccat gtgtagcggt gaaatgcgta gatatatgga agaacaccag 660

tggcgaaggc ggctgtctgg tctgtaactg acgctgaggc tcgaaagtat gggtagcaaa 720

caggattaga taccctggta gtccataccg taaacgatga atgctaagtg ttggagggtt 780

tccgcccttc agtgctgcag ctaacgcatt aagcattccg cctggggagt acggccgcaa 840

ggctgaaact caaaggaatt gacgggggcc cgcacaagcg gtggagcatg tggtttaatt 900

cgaagctacg cgaagaacct taccagtctt gacatactat gcaaatctaa gagattagac 960

gttcccttcg gggacatgga tacaggtggt gcatggttgt cgtcagctcg tgtcgtgaga 1020

tgttgggtta agtcccgcaa cgagcgcaac ccttattatc agttgccagc attaagttgg 1080

gcactctggt gagactgccg gtgacaaacc ggaggaaggt ggggatgacg tcaaatcatc 1140

atgcccctta tgacctgggc tacacacgtg ctacaatgga tggtacaacg agttgcgaac 1200

tcgcgagagt aagctaatct cttaaagcca ttctcagttc ggattgtagg ctgcaactcg 1260

cctacatgaa gtcggaatcg ctagtaatcg cggatcagca tgccgcggtg aatacgttcc 1320

cgggccttgt acacaccgcc cgtcacacca tgagagtttg taacacccaa a 1371